Acetyl-Boswellic Acids Are Novel Catalytic Inhibitors of Human Topoisomerases I and IIα
- 1Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm (Ta.S., B.B., W.Z., J.R.S., Th.S); and 2XanTec Analysensysteme, Muenster (E.G.), Germany
Abstract
Acetyl-boswellic acids (acetyl-BA) are pentacyclic triterpenes derived from the gum resin of frankincense. We have previously shown that these compounds are effective cytotoxic agents, acting through a mechanism that appears to involve the inhibition of topoisomerase activity. We have now investigated the mechanism of action of acetyl-BA and show that these compounds are more potent inhibitors of human topoisomerases I and IIα than camptothecin, and amsacrine or etoposide, respectively. Our data demonstrate that acetyl-BA and, to a lesser extent, some other pentacyclic triterpenes, such as betulinic acid, ursolic acid, and oleanolic acid, inhibit topoisomerases I and IIα through a mechanism that does not involve stabilization of the cleavable complex or the intercalation of DNA. Surface plasmon resonance analysis revealed that topoisomerases I and IIα bind directly to an immobilized derivative of acetyl-BA. This acetyl-BA derivative interacts with human topoisomerases through high-affinity binding sites yielding KD values of 70.6 nM for topoisomerase I and 7.6 nM for topoisomerase IIα. Based on our data, we propose that acetyl-BA inhibit topoisomerases I and IIα through competition with DNA for binding to the enzyme. Thus, acetyl-BA are a unique class of dual catalytic inhibitors of human topoisomerases I and IIα.
Footnotes
-
Send reprint requests to: Dr. Thomas Simmet, University of Ulm, Department of Pharmacology of Natural Products and Clinical Pharmacology, Helmholtzstr. 20, D-89081 Ulm, Germany. E-mail:thomas.simmet{at}medizin.uni-ulm.de
- Abbreviations:
- BA
- boswellic acid(s)
- AKβBA
- 3-O-acetyl-11-keto-β-boswellic acid
- AβBA
- 3-O-acetyl-β-boswellic acid
- EMSA
- electrophoretic mobility shift assay
- TAE
- Tris-acetate-EDTA
- biotinyl-AC-αBA
- 3-O-(N-(+)-biotinyl-6-aminocapropyl)-α-boswellic acid
- SPR
- surface plasmon resonance
- AαBA
- 3-O-acetyl-α-boswellic acid
-
- Received November 4, 1999.
- Accepted March 7, 2000.
- The American Society for Pharmacology and Experimental Therapeutics



